Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | PARG | Q86W56 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | AHR | P35869 | 1/20 | 0.42 |
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6983229 | 0.87 | HIF1A (0.55) | HIF1AMAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL6982924 | 0.84 | HIF1A (0.52) | HIF1AMAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL28409651 | 0.83 | HIF1A (0.70) | HIF1AMAPTPARGKDM4EAHR | |
| SCHEMBL6984202 | 0.83 | HIF1A (0.52) | HIF1AMAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL6981203 | 0.82 | HIF1A (0.57) | HIF1AMAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL27903825 | 0.81 | KDM4E (0.61) | HIF1AMAPTSMN1; SMN2NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL6978323 | 0.81 | KDM4E (0.50) | HIF1AMAPTNPC1RAB9APARG | |
| SCHEMBL4253620 | 0.77 | MAOB (0.66) | HIF1AMAPTSMN1; SMN2CA12CA9 | |
| SCHEMBL27903827 | 0.73 | MAPT (0.58) | HIF1AMAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL9826319 | 0.72 | KDM4E (0.40) | MAPTSMN1; SMN2NPC1RAB9ACA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030078251-A1 | Benzoxazepinones and their use as squalene synthase inhibitors | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 2003-04-24 | — | — | US | disclosed |
| EP-1292585-A1 | BENZOXAZEPINONES AND THEIR USE AS SQUALENE SYNTHASE INHIBITORS | Takeda Chemical Industries, Ltd. (JP) | 2003-03-19 | — | — | EP | disclosed |
| WO-2001098282-A1 | BENZOXAZEPINONES AND THEIR USE AS SQUALENE SYNTHASE INHIBITORS | TAKEDA CHEMICAL INDUSTRIES, LTD (JP) | 2001-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078251-A1 | Benzoxazepinones and their use as squalene synthase inhibitors | SQLE, CYP17A1, ACOX1 | HIF1A 2363/4885MAPT 4824/4885SMN1; SMN2 4321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.